Biogen is coming back home. The American company is opening a production plant in Switzerland that will employ 400 professionals. To this aim, the company will invest €0.9Bn ($1Bn) into the project.
Biogen was founded back in 1978 in Geneva, Switzerland, and now aims at expanding its manufacturing network by opening a biopharmaceutical plant in its home country. The company is partnering with the local administration of Solothurn to build an advance manufacturing facility in the area. This is going to propel the already-industrialized region, as the production plant will count 400 employees in its ranks as of 2019.
These new employees will add to the current 7,500 people located in 30 countries working for Biogen. The establishment of a highly advanced manufacturing facility could easily lead to the settlement of other companies. Switzerland is also home to Biogen’s international headquarters. Its European presence is completed with Biogen’s production plant in Denmark.
The company, the third biggest biotech worldwide, has a rapidly growing pipeline that certainly needs more capacity. Biogen is developing treatments for neurodegenerative diseases, hematologic conditions, and autoimmune disorders. According to FiercePharma, Biogen spokeswoman Kate Niazi-Sai stated: “The advantage of having an extensive manufacturing network is global diversity, so you have backup.”
Last May, Biogen obtained great results from its drug candidate that reduces amyloid plaques, one of the main symptoms of Alzheimer’s disease, leading the clinical program to Phase III. The targeted market could be worth up to €4,5Bn ($5Bn), according to analysts. The plant could be a critical asset for the potential blockbuster and Biogen’s global development.